SCHEMBL20856861

SCHEMBL20856861

Cc1c[nH]c(=S)[nH]c1=O.Nc1cc[nH]c(=S)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATAD2 Q6PL18 1/20 0.39
▸ UBE2N P61088 1/20 0.37
▸ TP53 P04637 1/20 0.35
▸ KDM3B Q7LBC6 1/20 0.34
▸ KMT2A Q03164 3/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS1 P29475 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ MEN1 O00255 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ GLA P06280 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ TNNI3 P19429 1/20 0.31
▸ TNNT2 P45379 1/20 0.31
▸ RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25450 0.78 — —
SCHEMBL25418259 0.78 ATAD2 (0.60) ATAD2UBE2NTP53KDM3BKMT2A
Thiouracil SCHEMBL22345877 0.77 TP53 (0.63) TP53DYRK1ABLM
SCHEMBL28216801 0.76 ATAD2 (0.58) ATAD2UBE2NTP53KDM3BKMT2A
SCHEMBL20718 0.76 — —
Thiouracil SCHEMBL4958659 0.75 TP53 (0.66) ATAD2UBE2NTP53KDM3BKMT2A
SCHEMBL11114659 0.74 — —
Thymine SCHEMBL2476233 0.74 ATAD2 (0.58) ATAD2KMT2ADYRK1ANOS3NOS1
Thymine SCHEMBL536790 0.74 ATAD2 (0.58) ATAD2KMT2ADYRK1ANOS3NOS1
Thymine SCHEMBL29232704 0.71 ATAD2 (0.76) ATAD2UBE2NKDM3BKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020197330-A1 COMPOSITION FOR TREATING HEMOPHILIA BY MEANS OF BLOOD COAGULATION FACTOR VIII GENE INVERSION CORRECTION 주식회사 툴젠 2020-10-01 — — WO disclosed
US-20200263204-A1 COMPOSITION FOR TREATING HEMOPHILIA A BY CRISPR/CAS SYSTEM OF REVERTING FVIII GENE INVERSION TOOLGEN INC (KR) 2020-08-20 — — US disclosed
EP-3690046-A2 COMPOSITION FOR TREATMENT OF HEMOPHILIA, COMPRISING CRISPR/CAS SYSTEM HAVING COAGULATION FACTOR VIII GENE INVERSION CORRECTION POTENTIAL Toolgen Incorporated (KR) 2020-08-05 — — EP disclosed
WO-2019066518-A2 COMPOSITION FOR TREATMENT OF HEMOPHILIA, COMPRISING CRISPR/CAS SYSTEM HAVING COAGULATION FACTOR VIII GENE INVERSION CORRECTION POTENTIAL 주식회사 툴젠 2019-04-04 — — WO disclosed
Send feedback